Neurologic factors predict a favorable valproate response in bipolar and schizoaffective disorders. Academic Article uri icon

start page

  • 311

end page

  • 313


  • The hypothesis that neurologic factors influence the response to valproate (divalproex sodium) in bipolar and schizoaffective disorders was tested. In 115 predominantly lithium-refractory inpatients, neurologic findings were recorded, and blind raters assessed valproate response from the medical record. Patients with a seizure history were much more likely to have a robust response to valproate (70%), when compared with patients without such history (34.6%). History of head injury and abnormal electroencephalographic findings also tended to be more common in those patients with good response. Overall, the group of patients with any neurologic abnormality exhibited a significantly higher rate of good response to valproate (43.6%) than did the neurologically normal group (24.3%). Bipolar or schizoaffective patients with abnormal neurologic features may represent a distinct subtype of illness and appear to be good candidates for valproate therapy.

date/time value

  • October 1994

PubMed Identifier

  • 7806685


  • 14


  • 5


  • Bipolar Disorder
  • Brain Damage, Chronic
  • Cohort Studies
  • Delirium, Dementia, Amnestic, Cognitive Disorders
  • Double-Blind Method
  • Electroencephalography
  • Epilepsy
  • Humans
  • Magnetic Resonance Imaging
  • Neurologic Examination
  • Psychotic Disorders
  • Retrospective Studies
  • Treatment Outcome
  • Valproic Acid